Novo Nordisk (NVO -7.78%) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. Despite strong growth and earnings momentum, the Danish biotech giant faces scrutiny over its positioning in the rapidly changing market for GLP-1 receptor agonists, as competition intensifies. Still, the company's fundamental strengths, including a solid financial outlook for the year ahead, make it worth a closer look. Is i ...